<DOC>
	<DOCNO>NCT02460224</DOCNO>
	<brief_summary>This study characterize safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) anti-tumor activity LAG525 single agent combination PDR001 adult patient solid tumor . The study consist dose escalation phase ( I ) determine maximum tolerate dose ( MTD ) recommend Phase 2 dose ( RP2D ) LAG525 single agent combination PDR001 , dose expansion phase ( II ) characterize treatment LAG525 single agent combination PDR001 MTD RP2D .</brief_summary>
	<brief_title>Safety Efficacy LAG525 Single Agent Combination With PDR001 Patients With Advanced Malignancies .</brief_title>
	<detailed_description />
	<criteria>Phase I part : Patients advanced/metastatic solid tumor , measurable nonmeasurable disease determine RECIST version 1.1 ( refer Appendix 1 ) , progress despite standard therapy intolerant standard therapy , standard therapy exist Phase II part : Patients advanced/metastatic solid tumor , least one measurable lesion determine RECIST version 1.1 , disease progression follow last prior therapy fit one follow group : Group 1 : NSCLC Group 2 : Melanoma Group 3 : Renal cancer Eastern Cooperative Oncology Group ( ECOG ) Performance Status â‰¤ 2 Patient must site disease amenable biopsy , candidate tumor biopsy accord treat institution 's guideline . History severe hypersensitivity reaction study treatment ingredient mAbs Active , know suspected autoimmune disease Active infection require systemic antibiotic therapy HIV infection . Active hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection Patients receive chronic treatment systemic steroid therapy , replacementdose corticosteroid set adrenal insufficiency Patients receive systemic treatment immunosupressive medication Use live vaccine infectious disease within 4 week initiation study treatment Systemic anticancer therapy within 2 week first dose study treatment . Presence symptomatic central nervous system ( CNS ) metastases CNS metastasis require local CNSdirected therapy increase dos corticosteroid within prior 2 week History druginduced pneumonitis current pneumonitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Renal cancer</keyword>
</DOC>